Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TPST Tempest Therapeutics Inc.

Market Closed 02-14 16:00:00 EST

0.9301

-0.0021

-0.23%

盘后0.9235

-0.0066-0.71%

19:59 EST

High0.9400	Low0.9100	Vol763.00K
Open0.9400	D1 Closing0.9322	Amplitude3.22%
Mkt Cap40.59M	Tradable Cap37.25M	Total Shares43.64M
T/O705.35K	T/O Rate1.91%	Tradable Shares40.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TPST","market":"US","secType":"STK","nameCN":"Tempest Therapeutics Inc.","latestPrice":0.9301,"timestamp":1739566800000,"preClose":0.9322,"halted":0,"volume":763000,"hourTrading":{"tag":"盘后","latestPrice":0.9235,"preClose":0.9301,"latestTime":"19:59 EST","volume":26669,"amount":25017.327574,"timestamp":1739581149538},"delay":0,"floatShares":40048230,"shares":43642072,"eps":-1.576823,"marketStatus":"Market Closed","change":-0.0021,"latestTime":"02-14 16:00:00 EST","open":0.94,"high":0.94,"low":0.91,"amount":705350.3142,"amplitude":0.032182,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.576823,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.9322,"preHourTrading":{"tag":"盘前","latestPrice":0.9348,"preClose":0.9322,"latestTime":"09:25 EST","volume":25076,"amount":23166.8751002,"timestamp":1739543113260},"postHourTrading":{"tag":"盘后","latestPrice":0.9235,"preClose":0.9301,"latestTime":"19:59 EST","volume":26669,"amount":25017.327574,"timestamp":1739581149538},"volumeRatio":0.5454400142982867,"impliedVol":1.9242,"impliedVolPercentile":0.6096},"requestUrl":"/m/hq/s/TPST/wiki","defaultTab":"wiki","newsList":[{"id":"2510286921","title":"Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2510286921","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510286921?lang=en_us&edition=fundamental","pubTime":"2025-02-10 23:30","pubTimestamp":1739201421,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics  said Monday the US Food and Drug Administration granted fast track designation to amezalpat for the potential treatment of hepatocellular carcinoma, a type of liver cancer.The company said the designation allows for increased communication with the FDA and potential eligibility for accelerated approval and priority review. The designation follows an orphan drug designation in January, Tempest added.Tempest said amezalpat is being evaluated in combination with atezolizumab and bevacizumab in a global phase 1b/2 trial for first-line treatment of unresectable or metastatic hepatocellular carcinoma.Shares of the company were up 1.8% in recent Monday trading.Price: 0.89, Change: +0.02, Percent Change: +1.77","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4104","IE00BFXG0V08.USD","TPST","FAST","IE00BYQQ9H92.USD","BK4139","IE00B5TLWC47.USD","BK4585","BK4567","BK4588"],"gpt_icon":0},{"id":"2510985445","title":"Tempest Therapeutics granted FTD from FDA for amezalpat","url":"https://stock-news.laohu8.com/highlight/detail?id=2510985445","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510985445?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:06","pubTimestamp":1739192781,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, an or...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-granted-ftd-from-fda-for-amezalpat?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-granted-ftd-from-fda-for-amezalpat?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IE00BFXG0V08.USD","LENZ","BK4567","BK4104","TPST","BK4588","BK4585","FAST","IE00BYQQ9H92.USD","IE00B5TLWC47.USD"],"gpt_icon":0},{"id":"2510548048","title":"BRIEF-Tempest Granted Fast Track Designation From The U.S. Food And Drug Administration For Amezalpat","url":"https://stock-news.laohu8.com/highlight/detail?id=2510548048","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510548048?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:04","pubTimestamp":1739192647,"startTime":"0","endTime":"0","summary":"BRIEF-Tempest Granted Fast Track Designation From The U.S. Food And Drug Administration For Amezalpat Feb 10 (Reuters) - Tempest Therapeutics TPST.O:TEMPEST GRANTED FAST TRACK DESIGNATION FROM THE U.S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA2GP0T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2510851070","title":"Tempest Granted Fast Track Designation From the U.S. Food and Drug Administration for Amezalpat to Treat Patients With Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2510851070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510851070?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:00","pubTimestamp":1739192400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA2GP0T6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2509377472","title":"Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509377472","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509377472?lang=en_us&edition=fundamental","pubTime":"2025-02-08 05:57","pubTimestamp":1738965471,"startTime":"0","endTime":"0","summary":"Feb 7 (Reuters) - Tempest Therapeutics Inc ::*TEMPEST REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 07-FEB-202521:30:00.25 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nRSD2d05y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2501231748","title":"BRIEF-Tempest Receives Orphan Drug Designation From U.S. FDA For Amezalpat","url":"https://stock-news.laohu8.com/highlight/detail?id=2501231748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501231748?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:29","pubTimestamp":1736170182,"startTime":"0","endTime":"0","summary":"BRIEF-Tempest Receives Orphan Drug Designation From U.S. FDA For AmezalpatJan 6  - Tempest Therapeutics Inc TPST.O:TEMPEST RECEIVES ORPHAN DRUG DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR AMEZALPAT TO TREAT PATIENTS WITH HEPATOCELLULAR CARCINOMA Source text: nGNX9DyhdgFurther company coverage: TPST.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA7K4CBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2501239332","title":"Tempest Receives Orphan Drug Designation From the U.S. Food and Drug Administration for Amezalpat to Treat Patients With Hepatocellular Carcinoma (Hcc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239332","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239332?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:00","pubTimestamp":1736168405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA7K4CBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2492675868","title":"Tempest Therapeutics’ PPARalpha inhibitor receives FDA orphan designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2492675868","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492675868?lang=en_us&edition=fundamental","pubTime":"2024-12-17 07:55","pubTimestamp":1734393308,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics (TPST)’ PPARalpha inhibitor, a treatment of hepatocellular carcinoma, received FDA orphan designation, according to a post on ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-pparalpha-inhibitor-receives-fda-orphan-designation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-pparalpha-inhibitor-receives-fda-orphan-designation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","TPST"],"gpt_icon":0},{"id":"2489261562","title":"Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2489261562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489261562?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:30","pubTimestamp":1733520600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nTUABLWPJ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BKPKM429.USD","BK4585","BK4112","LU2210150020.SGD","LU2095319765.USD","NDAQ","TPST","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","BK4139","IE00BGHQF748.EUR","LU2210149790.SGD"],"gpt_icon":0},{"id":"2486841085","title":"Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2486841085","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486841085?lang=en_us&edition=fundamental","pubTime":"2024-11-27 18:20","pubTimestamp":1732702836,"startTime":"0","endTime":"0","summary":"Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Tempest Therapeutics, Inc. , it sends a favourable message to the company's shareholders.While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.Tempest Therapeutics Insider Transactions Over The Last Year. Of course Tempest Therapeutics may not be the best stock to buy. So you may wish to see this free coll","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/favourable-signals-tempest-therapeutics-numerous-102036134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TPST","BK4139","LENZ"],"gpt_icon":1},{"id":"2483269001","title":"Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483269001","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483269001?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:35","pubTimestamp":1731501300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TPST/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 07:35 ET (12:35 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","LENZ"],"gpt_icon":0},{"id":"2483001770","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483001770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483001770?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:32","pubTimestamp":1731501131,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Quanterix (QTRX – Research Report), Nevro Corp (NV...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-quanterix-qtrx-nevro-corp-nvro-and-tempest-therapeutics-tpst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-quanterix-qtrx-nevro-corp-nvro-and-tempest-therapeutics-tpst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVRO","BK4139","BK4121","BK4082","QTRX","TPST","HCSG","BK4137"],"gpt_icon":0},{"id":"2483078471","title":"Tempest Therapeutics Inc :  Piper Sandler Cuts Target Price to $5 From $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2483078471","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483078471?lang=en_us&edition=fundamental","pubTime":"2024-11-13 17:15","pubTimestamp":1731489354,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK0V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2483740065","title":"Tempest Therapeutics Q3 EPS $(0.41) Misses $(0.35) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483740065","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483740065?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:15","pubTimestamp":1731449735,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics Q3 EPS $(0.41) Misses $(0.35) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41923538/tempest-therapeutics-q3-eps-0-41-misses-0-35-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TPST"],"gpt_icon":0},{"id":"2483057195","title":"Tempest Therapeutics Q3 EPS USD -0.41 VS. Ibes Estimate USD -0.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2483057195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483057195?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:21","pubTimestamp":1731446462,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nPLX414D53:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0},{"id":"2482704319","title":"BRIEF-Tempest Receives FDA Study May Proceed For Pivotal Phase 3 Trial Of Amezalpat Combination Therapy For The Treatment Of First-Line Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2482704319","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482704319?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:21","pubTimestamp":1731417686,"startTime":"0","endTime":"0","summary":"Nov 12  - Tempest Therapeutics Inc   :   * TEMPEST RECEIVES FDA STUDY MAY PROCEED FOR PIVOTAL PHASE 3 TRIAL OF AMEZALPAT COMBINATION THERAPY FOR THE TREATMENT OF FIRST-LINE HEPATOCELLULAR CARCINOMA   * TEMPEST RECEIVES FDA STUDY MAY PROCEED FOR PIVOTAL PHASE 3 TRIAL OF AMEZALPAT COMBINATION THERAPY FOR THE TREATMENT OF FIRST-LINE HEPATOCELLULAR CARCINOMA   * TEMPEST THERAPEUTICS INC - PHASE 3 STUDY EXPECTED TO START IN Q1 2025Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"gpt_icon":0},{"id":"2480580020","title":"Tempest Therapeutics Inc    expected to post a loss of 36 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2480580020","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480580020?lang=en_us&edition=fundamental","pubTime":"2024-11-04 23:48","pubTimestamp":1730735303,"startTime":"0","endTime":"0","summary":"* Tempest Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on November 6 (estimated) for the period ending September 30 2024   *    * LSEG's mean analys","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TPST"],"gpt_icon":1},{"id":"2474106743","title":"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2474106743","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474106743?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:30","pubTimestamp":1728646228,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report), Allakos (ALLK – Research...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-allakos-allk-and-tempest-therapeutics-tpst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-allakos-allk-and-tempest-therapeutics-tpst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TPST","BK4137","BK4139","HCSG","BK4588","BK4548","BK4585","ALLK","ALNY"],"gpt_icon":0},{"id":"2474671020","title":"Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2474671020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474671020?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:30","pubTimestamp":1728646211,"startTime":"0","endTime":"0","summary":"In a report released today, George Farmer from Scotiabank maintained a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/scotiabank-sticks-to-their-buy-rating-for-tempest-therapeutics-tpst-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/scotiabank-sticks-to-their-buy-rating-for-tempest-therapeutics-tpst-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TPST"],"gpt_icon":0},{"id":"2474474502","title":"Tempest Therapeutics Shares up 12.6% at $1.74 After Agreement to Test Its Liver Cancer Drug With Roche's Therapy in Pivotal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2474474502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474474502?lang=en_us&edition=fundamental","pubTime":"2024-10-10 21:31","pubTimestamp":1728567098,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241010:nFWN3LM0NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tempesttx.com","stockEarnings":[{"period":"1week","weight":0.0613},{"period":"1month","weight":0.0417},{"period":"3month","weight":0.0452},{"period":"6month","weight":-0.3541},{"period":"1year","weight":-0.7663},{"period":"ytd","weight":0.1146}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018143},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.011198},{"month":3,"riseRate":0.545455,"avgChangeRate":0.034268},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.129414},{"month":5,"riseRate":0.5,"avgChangeRate":0.018957},{"month":6,"riseRate":0.25,"avgChangeRate":-0.134588},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.032621},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.089732},{"month":9,"riseRate":0.5,"avgChangeRate":-0.067189},{"month":10,"riseRate":0.5,"avgChangeRate":1.025612},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.031071},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.059181}],"exchange":"NASDAQ","name":"Tempest Therapeutics Inc.","nameEN":"Tempest Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tempest Therapeutics Inc.,TPST,Tempest Therapeutics Inc.股票,Tempest Therapeutics Inc.股票老虎,Tempest Therapeutics Inc.股票老虎国际,Tempest Therapeutics Inc.行情,Tempest Therapeutics Inc.股票行情,Tempest Therapeutics Inc.股价,Tempest Therapeutics Inc.股市,Tempest Therapeutics Inc.股票价格,Tempest Therapeutics Inc.股票交易,Tempest Therapeutics Inc.股票购买,Tempest Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction